Genetic Factors Influencing Warfarin Dose in Black‐African Patients: A Systematic Review and Meta‐Analysis
- 28 January 2020
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 107 (6) , 1420-1433
Abstract
Warfarin is the most commonly used oral anticoagulant in sub‐Saharan Africa. Dosing is challenging due to a narrow therapeutic index and high interindividual variability in dose requirements. To evaluate the genetic factors affecting warfarin dosing in black‐Africans, we performed a meta‐analysis of 48 studies (2,336 patients). Significant predictors forCYP2C9and stable dose included rs1799853 (CYP2C9*2), rs1057910 (CYP2C9*3), rs28371686 (CYP2C9*5), rs9332131 (CYP2C9*6), and rs28371685 (CYP2C9*11) reducing dose by 6.8, 12.5, 13.4, 8.1, and 5.3 mg/week, respectively.VKORC1variants rs9923231 (‐1639G>A), rs9934438 (1173C>T), rs2359612 (2255C>T), rs8050894 (1542G>C), and rs2884737 (497T>G) decreased dose by 18.1, 21.6, 17.3, 11.7, and 19.6 mg/week, respectively, whereas rs7294 (3730G>A) increased dose by 6.9 mg/week. Finally, rs12777823 (CYP2Cgene cluster) was associated with a dose reduction of 12.7 mg/week. Few studies were conducted in Africa, and patient numbers were small, highlighting the need for further work in black‐Africans to evaluate genetic factors determining warfarin response.Keywords
This publication has 50 references indexed in Scilit:
- Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association studyThe Lancet, 2013
- Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-AnalysisPLOS ONE, 2012
- Genomic Ancestry of North Africans Supports Back-to-Africa MigrationsPLOS Genetics, 2012
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin DosingClinical Pharmacology & Therapeutics, 2011
- Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patientsEuropean Journal of Clinical Pharmacology, 2011
- The Missing Association: Sequencing-Based Discovery of Novel SNPs in VKORC1 and CYP2C9 That Affect Warfarin Dose in African AmericansClinical Pharmacology & Therapeutics, 2011
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic DataNew England Journal of Medicine, 2009
- Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirementBlood, 2008
- Influence of CYP2C9 and VKORC1 on Warfarin Dose, Anticoagulation Attainment and Maintenance Among European–Americans and African–AmericansPharmacogenomics, 2008
- Association of warfarin dose with genes involved in its action and metabolismHuman Genetics, 2006